Silver Grove Financial Group
BCAX icon

Silver Grove Financial Group’s Bicara Therapeutics BCAX Stock Holding History

Silver Grove Financial Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.93K Buy
265
+93
+54% +$2.33K ﹤0.01% 1303
2026
Q2 		$5.11K Buy
+172
New +$3.84K ﹤0.01% 1191

Other funds holding BCAX

Red Tree Management
Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Silver Grove Financial Group's BCAX Position: Q3 2026 in Review

Silver Grove Financial Group increased its Bicara Therapeutics (BCAX) stake by 54% in Q3 2026, buying an estimated $2.33K and bringing the position to 265 shares worth $4.93K. The position accounts for ﹤0.01% of the portfolio, ranked #1303.

Silver Grove Financial Group first reported a position in BCAX in Q2 2026 and has held it in 2 quarters since. The position peaked at $5.11K in Q2 2026. 65 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

  • Silver Grove Financial Group held 265 shares of Bicara Therapeutics worth $4.93K as of Q3 2026.
  • Silver Grove Financial Group bought 93 Bicara Therapeutics shares in Q3 2026, an estimated $2.33K.
  • Bicara Therapeutics made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q3 2026, its #1303 holding.
  • Silver Grove Financial Group first reported a position in Bicara Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Silver Grove Financial Group's Bicara Therapeutics position peaked at $5.11K in Q2 2026.
  • 65 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Silver Grove Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.